BioMarin也迅速跟进迭代研发，其升级版在研产品BMN333同样旨在实现周剂注射。早期临床结果显示BMN333的AUC水平高于其他长效CNP研究的3倍以上，公司研发主管Greg Friberg表示该药对标的正是TransCon-CNP。
Nature, Published online: 24 February 2026; doi:10.1038/s41586-026-10294-0，更多细节参见快连下载安装
They hardly meant has come to be，推荐阅读夫子获取更多信息
You can start your design by choosing from a variety of ready-made templates, searching for a template matching your needs, or working with a blank template.